Kurt A Jaeckle

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
    Vinay K Puduvalli
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 65:259-66. 2003
  2. ncbi request reprint Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment
    Kurt A Jaeckle
    Department of Neurology and Oncology, Mayo Clinic Jacksonville, Jacksonsville, FL 32224, USA
    Semin Oncol 33:312-23. 2006
  3. ncbi request reprint Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response
    Kurt A Jaeckle
    Mayo Clinic, Rochester, NY, USA
    J Clin Oncol 24:1246-52. 2006
  4. pmc Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma
    Kurt A Jaeckle
    Mayo Clinic, Jacksonville, FL 32224, USA
    Neurology 73:1207-13. 2009
  5. pmc Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM
    Kurt A Jaeckle
    Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Neurooncol 99:73-80. 2010
  6. doi request reprint Neurologic manifestations of neoplastic and radiation-induced plexopathies
    Kurt A Jaeckle
    Department of Neurology and Oncology, Mayo Clinic Florida, Jacksonville, Florida 32224, USA
    Semin Neurol 30:254-62. 2010
  7. ncbi request reprint Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
    Kurt A Jaeckle
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 21:2305-11. 2003
  8. doi request reprint Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis
    K A Jaeckle
    Mayo Clinic, Cannaday 2 E, Jacksonville, FL 32224, USA
    J Neurooncol 104:253-9. 2011
  9. pmc Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    Paul D Brown
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 26:5603-9. 2008
  10. pmc North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme
    Jann N Sarkaria
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:468-75. 2011

Detail Information

Publications39

  1. ncbi request reprint Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival
    Vinay K Puduvalli
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Oncology 65:259-66. 2003
    ..In this multicenter retrospective study, we analyzed the clinical characteristics of patients with AO to identify prognostic factors that influence time to progression (TTP) and survival...
  2. ncbi request reprint Neoplastic meningitis from systemic malignancies: diagnosis, prognosis and treatment
    Kurt A Jaeckle
    Department of Neurology and Oncology, Mayo Clinic Jacksonville, Jacksonsville, FL 32224, USA
    Semin Oncol 33:312-23. 2006
    ....
  3. ncbi request reprint Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response
    Kurt A Jaeckle
    Mayo Clinic, Rochester, NY, USA
    J Clin Oncol 24:1246-52. 2006
    ....
  4. pmc Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma
    Kurt A Jaeckle
    Mayo Clinic, Jacksonville, FL 32224, USA
    Neurology 73:1207-13. 2009
    ..However, the resultant effect of such induction on patient outcome has received limited study...
  5. pmc Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM
    Kurt A Jaeckle
    Mayo Clinic Florida, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    J Neurooncol 99:73-80. 2010
    ..This regimen was not significantly active and radiosensitization was not observed. Non-EIAC patients with UGT1A1*28 variant alleles appear particularly sensitive to toxicity from irinotecan...
  6. doi request reprint Neurologic manifestations of neoplastic and radiation-induced plexopathies
    Kurt A Jaeckle
    Department of Neurology and Oncology, Mayo Clinic Florida, Jacksonville, Florida 32224, USA
    Semin Neurol 30:254-62. 2010
    ..These measures often offer temporary (months) relief or improvement. Physicians treating these patients should focus on effective management of pain and prevention of complications of immobility produced by the neuromuscular dysfunction...
  7. ncbi request reprint Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study
    Kurt A Jaeckle
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 21:2305-11. 2003
    ..This phase II trial evaluated efficacy and toxicity of combination temozolomide and cRA treatment in recurrent MG...
  8. doi request reprint Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis
    K A Jaeckle
    Mayo Clinic, Cannaday 2 E, Jacksonville, FL 32224, USA
    J Neurooncol 104:253-9. 2011
    ..From time of recurrence, OS was not significantly different for those with primary versus secondary GBM, and it may thus be reasonable include patients with secondary GBM in clinical therapeutic trials for recurrent disease...
  9. pmc Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177
    Paul D Brown
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 26:5603-9. 2008
    ..Erlotinib, a selective EGFR inhibitor, was combined with temozolomide (TMZ) and radiotherapy (RT) in a phase I/II trial...
  10. pmc North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme
    Jann N Sarkaria
    Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 81:468-75. 2011
    ..On the basis of promising preclinical data, the safety and tolerability of therapy with the mTOR inhibitor RAD001 in combination with radiation (RT) and temozolomide (TMZ) was evaluated in this Phase I study...
  11. pmc The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
    Karla V Ballman
    Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Neuro Oncol 9:29-38. 2007
    ..Finally, there was a strong association between progression-free survival status and overall survival. PFS6 seems to be a reasonable end point for phase II trials in patients with recurrent glioblastoma...
  12. doi request reprint Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074
    Joon H Uhm
    Division of Neuro Oncology, Department of Neurology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 80:347-53. 2011
    ..In the current study, we evaluated gefitinib, a potent EGFR inhibitor, in the treatment of adults with newly diagnosed GBM...
  13. pmc Combination of temsirolimus (CCI-779) with chemoradiation in newly diagnosed glioblastoma multiforme (GBM) (NCCTG trial N027D) is associated with increased infectious risks
    Jann N Sarkaria
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Clin Cancer Res 16:5573-80. 2010
    ..The mammalian target of rapamycin (mTOR) functions within the phosphoinositide 3-kinase/Akt signaling pathway as a critical modulator of cell survival...
  14. pmc Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
    Marta Santisteban
    Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    J Neurooncol 92:165-75. 2009
    ....
  15. pmc Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study
    Evanthia Galanis
    Mayo Clinic, Gonda 10 141, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 27:2052-8. 2009
    ..Vorinostat, a histone deacetylase inhibitor, represents a rational therapeutic target in glioblastoma multiforme (GBM)...
  16. ncbi request reprint Detrimental effects of tumor progression on cognitive function of patients with high-grade glioma
    Paul D Brown
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:5427-33. 2006
    ..To assess the cognitive performance of high-grade glioma patients, prospectively collected cognitive performance data were analyzed...
  17. ncbi request reprint Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme
    Morris D Groves
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1383-8. 2002
    ....
  18. ncbi request reprint Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177
    Sunil Krishnan
    Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA
    Int J Radiat Oncol Biol Phys 65:1192-9. 2006
    ..To evaluate the toxicity and maximum tolerated dose (MTD) of erlotinib plus radiation therapy (RT) in patients with glioblastoma multiforme (GBM) in a multicenter phase I trial...
  19. ncbi request reprint Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas
    Victor A Levin
    Department of Neuro Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 9:981-90. 2003
    ....
  20. ncbi request reprint Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
    Evanthia Galanis
    Mayo Clinic and Mayo Foundation, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 23:5294-304. 2005
    ..Temsirolimus (CCI-779) is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR) and represents a rational therapeutic target against glioblastoma multiforme (GBM)...
  21. ncbi request reprint Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients
    Nicole E Marshall
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Neurooncol 77:315-20. 2006
    ..To assess the effect of cisplatin (CDDP) plus concurrent radiation therapy on hearing loss...
  22. pmc Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
    Wenting Wu
    Division of Biostatistics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Neuro Oncol 12:164-72. 2010
    ..Other important variables for one or more endpoints included age, PS, and DxTime. Neither type of treatment center nor initial low-grade histology was identified as a major predictor for any endpoint...
  23. pmc Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma
    Liuyan Jiang
    Department of Pathology, Mayo Clinic, Jacksonville, Florida 32224, USA
    Int J Clin Exp Pathol 5:72-6. 2012
    ..It is characterized by a very aggressive clinical course, and a widespread multifocal involvement of the CNS. Our case shows that a DLBCL/BL can manifest in the CNS alone without any systemic involvement...
  24. ncbi request reprint Nonconvulsive status epilepticus in metastatic CNS disease
    Svetlana Blitshteyn
    Department of Neurology, Mayo Clinic, Jacksonville, FL 3222, USA
    Neurology 66:1261-3. 2006
    ..NCSE should be considered in the differential diagnosis of acute mental status change in patients with metastatic CNS disease...
  25. pmc Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
    Mark R Gilbert
    Mark R Gilbert, Kenneth D Aldape, Terri S Armstrong, Jeffrey S Wefel, Anita Mahajan, and Paul D Brown, University of Texas MD Anderson Cancer Center Terri S Armstrong, University of Texas Health Science Center School of Nursing, Houston, TX Meihua Wang and Minhee Won, Radiation Therapy Oncology Group Statistical Center, Philadelphia, PA Roger Stupp and Monika E Hegi, Lausanne University Hospitals, Lausanne, Switzerland Kurt A Jaeckle, Mayo Clinic Florida, Jacksonville, FL Deborah T Blumenthal, Tel Aviv Medical Center, Tel Aviv Tzahala Tzuk Shina, Rambam Medical Center, Haifa, Israel Christopher J Schultz, Medical College of Wisconsin, Milwaukee, WI Sara Erridge, University of Edinburgh, Edinburgh, Scotland Brigitta G Baumert, Maastricht University Medical Center, Maastricht, the Netherlands Kristen I Hopkins, University Hospitals Bristol, Bristol, United Kingdom Arnab Chakravarti, Arthur G James Cancer Hospital Ohio State University Comprehensive Cancer Center, Columbus,
    J Clin Oncol 31:4085-91. 2013
    ..This trial tested whether DD temozolomide improves overall survival (OS) or progression-free survival (PFS) in patients with newly diagnosed GBM...
  26. pmc Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial
    Evanthia Galanis
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 19:4816-23. 2013
    ....
  27. doi request reprint North Central Cancer Treatment Group--achievements and perspectives
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 35:530-44. 2008
    ....
  28. pmc Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5
    Sherry L Wolf
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 28:5182-7. 2010
    ..This trial was conducted on the basis of preliminary data that a urea/lactic acid-based topical keratolytic agent (ULABTKA) may prevent HFS...
  29. ncbi request reprint Improving the outcome of patients with leptomeningeal cancer: new clinical trials and experimental therapies
    Kurt A Jaeckle
    Mayo Clinic, Jacksonville, Florida 32224, USA
    Cancer Treat Res 125:181-93. 2005
    ..Furthermore, there is debate as to the optimal strategy of drug delivery for leptomeningeal tumor...
  30. ncbi request reprint An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis
    Kurt A Jaeckle
    Mayo Clinic, Jacksonville, FL, USA
    J Neurooncol 57:231-9. 2002
    ..The once in every 2-week-dosing interval offers an advantage over conventional schedules (2-3 doses/week) used for other agents available for intrathecal injection...
  31. ncbi request reprint Removal of an orbital metallic foreign body to facilitate magnetic resonance imaging: technical case report
    H Gordon Deen
    Department of Neurosurgery, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA
    Neurosurgery 58:E999; discussion E999. 2006
    ..In such cases, the usual clinical strategy is to manage the patient without the benefit of MRI scans and, instead, to rely on less sensitive imaging modalities in particular computed tomographic scanning...
  32. ncbi request reprint Neurological manifestations of neoplastic and radiation-induced plexopathies
    Kurt A Jaeckle
    Department of Neurology and Oncology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Semin Neurol 24:385-93. 2004
    ..Efforts should be made to provide adequate pain control, maximize remaining neurological function, and prevent complications of immobility produced by the neuromuscular dysfunction...
  33. pmc Pathway analysis of primary central nervous system lymphoma
    Han W Tun
    Department of Hematology and Oncology, Mayo Clinic Jacksonville, FL 32224, USA
    Blood 111:3200-10. 2008
    ..The gene expression signature discovered in our study may represent a true "CNS signature" because we contrasted PCNSL with wide-spectrum non-CNS DLBCL on a genomic scale and performed an in-depth bioinformatic analysis...
  34. doi request reprint Is there an association between meningioma and hormone replacement therapy?
    Svetlana Blitshteyn
    Department of Neurology and Biostatistics Unit, Mayo Clinic, Jacksonville, FL 32224, USA
    J Clin Oncol 26:279-82. 2008
    ..The goal of this study was to investigate whether there is an association between a diagnosis of meningioma and either current or past HRT use in women...
  35. pmc Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:44-54. 2004
    ..A phase 2 study of patients with recurrent malignant glioma is ongoing to assess the efficacy of CPT-11 when the dose is stratified according to the use of EIAEDs...
  36. pmc Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
    Michael D Prados
    Department of Neurological Surgery, University of California at San Francisco, San Francisco, CA 94143, USA
    Neuro Oncol 6:33-7. 2004
    ..We conclude that BCNU plus temozolomide when used in these doses and schedule has only modest activity, with significant toxicity, and appears to be no more effective than single-agent temozolomide...
  37. ncbi request reprint Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis
    Bernard F Cole
    Department of Community and Family Medicine, Dartmouth Medical School, Lebanon, New Hampshire, USA
    Cancer 97:3053-60. 2003
    ..The authors evaluated the trade-off between toxicity and improved clinical outcome...
  38. ncbi request reprint Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial
    Susan M Chang
    Department of Neurological Surgery, Neuro Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA
    Cancer 100:1712-6. 2004
    ..The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG...
  39. ncbi request reprint Status epilepticus in patients with CNS metastases
    Svetlana Blitshteyn
    Arch Neurol 64:916; author reply 916-7. 2007